Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines - PubMed (original) (raw)

Comparative Study

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

Cuiqing Ma et al. Vaccine. 2014.

Abstract

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle East and Europe, raising a serious concern about its pandemic potential. Therefore, development of effective vaccines is crucial for preventing its further spread and future pandemic. Our previous study has shown that subcutaneous (s.c.) vaccination of a recombinant protein containing receptor-binding domain (RBD) of MERS-CoV S fused with Fc of human IgG (RBD-Fc) induced strong systemic neutralizing antibody responses in vaccinated mice. Here, we compared local and systemic immune responses induced by RBD-Fc via intranasal (i.n.) and s.c. immunization pathways. We found that i.n. vaccination of MERS-CoV RBD-Fc induced systemic humoral immune responses comparable to those induced by s.c. vaccination, including neutralizing antibodies, but more robust systemic cellular immune responses and significantly higher local mucosal immune responses in mouse lungs. This study suggests the potential of developing MERS-CoV RBD protein into an effective and safe mucosal candidate vaccine for prevention of respiratory tract infections caused by MERS-CoV.

Keywords: MERS-CoV; Mucosal immune response; Neutralizing antibody; Receptor-binding domain; Spike protein; Systemic immune response.

Copyright © 2014 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Mouse immunization, sample collection and immune response detection. Four groups of mice (5 mice/group) were respectively s.c. or i.n. prime-vaccinated with MERS-CoV RBD-Fc protein plus adjuvant as the vaccine groups, or with PBS plus adjuvant as their respective controls. Mice were initially boosted twice at 21 and 42 days and further boosted at the end of the 3rd and 6th months with the same immunogens and vaccination routes, and sera were collected on a monthly basis. Ten days post-last vaccination, mouse sera and lung wash were collected to detect IgG, subtypes and IgA antibodies by ELISA, or neutralizing antibodies by neutralization assay. Mouse splenocytes collected at 10 days post-last vaccination were detected for cellular immune responses by flow cytometric analysis.

Fig. 2

Fig. 2

Detection of total IgG antibody responses by ELISA in vaccinated mouse sera and lung wash. (A) Reactivity of serum IgG antibodies specific to MERS-CoV S1 protein. The MERS S1-specific IgG was detected using sera (1:3000) from mice before (pre-immune) and 10 days post-1st, -2nd, and -last vaccination. The data are presented as mean A450 ± standard deviation (SD) of five mice per group. (B) Ability of IgG binding to MERS-CoV S1 protein was detected using sera from 10 days post-last vaccination. The data are presented as mean A450 ± SD of five mice per group at various dilution points. MERS-CoV S1- (C) or S-RBD- (D) specific IgG endpoint titers were detected using sera from 10 days post-last vaccination. The data are presented as geometric mean titer (GMT) ± SD of five mice per group. (E) Detection of long-term antibody responses using sera collected at 0, 1, 2, 3, 4, 6 months and 10 days post-last vaccination. The data are presented as mean (IgG endpoint titers) ± SD of five mice per group. (F) Reactivity of lung wash IgG antibodies specific to MERS-CoV S1 was detected using mouse lung wash (1:1000) 10 days post-last vaccination. The data are presented as mean A450 ± SD of five mice per group.

Fig. 3

Fig. 3

Detection of IgG subtypes by ELISA in vaccinated mouse sera. MERS-CoV S1-specific IgG1 (A), IgG2a (B) and IgG3 (C) antibodies induced by i.n. or s.c. vaccination were detected using sera from 10 days post-last vaccination. The endpoint titer of each sample was determined as the highest dilution that yielded an OD450 nm value greater than twice that of similarly diluted serum sample collected pre-immunization with an optical density of 0.15. The data are presented as GMT ± SD of five mice per group.

Fig. 4

Fig. 4

Detection of IgA antibody responses by ELISA in vaccinated mouse lung wash and sera. The MERS-CoV S1-specific IgA antibodies induced by i.n. or s.c. vaccination were detected using mouse lung wash (1:1000) (A) or serial diluted sera (B) 10 days post-last vaccination. The data from lung wash are presented as mean A450 ± SD of five mice per group. The endpoint titer of each serum sample was determined as the highest dilution that yielded an OD450 nm value greater than twice that of similarly diluted serum sample collected pre-immunization with an optical density of 0.15. The data from serum samples are presented as GMT ± SD of five mice per group.

Fig. 5

Fig. 5

Detection of cellular immune responses by flow cytometric analysis in spleens of vaccinated mice 10 days post-last vaccination. MERS-CoV S1-specific T cell responses were detected for frequencies of IL-2- and IFN-γ-producing CD4+ splenocytes (A) and CD8+ splenocytes (B) by cell surface marker, followed by intracellular cytokine staining using flow cytometric analysis. Splenocytes from MERS-CoV RBD-Fc-vaccinated mice were incubated with recombinant MERS-CoV S1 protein (panels a and b in A and B), or SARS-CoV RBD protein (as the control) (panels e and f in A and B). Splenocytes of mice from the PBS control were also stimulated with MERS-CoV S1 (panels c and d in A and B) or SARS-CoV RBD protein (panels g and h in A and B). Frequencies of IL-2- and IFN-γ-producing cells were expressed as percentages of CD4+ or CD8+ T cells. The data in the upper left or the bottom right corner of each graph represent the frequencies of IL-2- or IFN-γ-producing CD4+ or CD8+ T cells. The samples were tested in triplicate and presented as mean ± SD (five mice per group). The numbers in bold indicate significant difference between corresponding s.c. and i.n. vaccination groups. The experiments were repeated for three times, and similar results were obtained.

Fig. 6

Fig. 6

Detection of neutralizing antibody titers by neutralization assay in vaccinated mouse samples. Sera (A) and lung wash (1:1000 dilution in PBS during collection) (B) from i.n. or s.c. vaccination groups were collected at 10 days post-last vaccination and analyzed for neutralization of MERS-CoV infection in Vero E6 cells. Neutralizing antibody titers were expressed as the reciprocal of the highest dilution of serum that completely inhibited virus-induced CPE in at least 50% of the wells (NT50), and are presented as GMT ± SD from five mice per group.

Similar articles

Cited by

References

    1. Zaki A.M., van B.S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed
    1. Memish Z.A., Zumla A.I., Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med. 2013;369:884–886. - PubMed
    1. Assiri A., McGeer A., Perl T.M., Price C.S., Al Rabeeah A.A., Cummings D.A. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407–416. - PMC - PubMed
    1. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. - PMC - PubMed
    1. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources